GRI Bio, Inc. (GRI): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

GRI Bio, Inc. (GRI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) On November 4, 2026, at 11:00 a.m. Eastern Time, GRI Bio, Inc. (the “Company”) held its 2026 Annual Meeting of Stockhol

Event · Shareholder vote
Original reporting
Published Nov 4, 2026, 10:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 10:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$GRI
Neutral
high confidence
Mentioned
$GRI
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$GRINeutralLow
01

Why it matters

The amendment increases authorized shares by 546,529, modestly diluting existing equity and may affect share price perception.

02

Market read

Primary corporate action with modest dilution risk; limited immediate trading impact.

03

What to watch

The extended evergreen provision to 2036 could enable future equity grants tied to long‑term milestones.

Relevance 6/10Novelty 6/10Timing: same‑day filing

Background

GRI Bio filed an 8‑K reporting amendments to its equity incentive plan and director elections, a routine corporate governance update.

Company-level read

Ticker impact

$GRINeutralHigh confidence
Context

SEC Form 8‑K discloses amendment to the 2018 Equity Incentive Plan and election of new directors, a primary corporate action for GRI Bio.

Expected impact

likely slight downward pressure as the market prices potential dilution

Evidence & confidence

First‑report filing; no immediate financial impact disclosed, but dilution risk is typical for such plan expansions.

Market effects

Minimal; biotech sector sees routine equity plan updates without broader impact.

U.S. market only, no regional ripple.

Low; limited to GRI Bio shareholders.

Counterpoint

Investors may view the plan expansion as a sign of upcoming hiring or acquisitions, potentially supporting upside.

Key entities

  • GRI Bio, Inc.

    Biotech firm filing the 8‑K.

  • W. Marc Hertz, Ph.D.

    Elected director.

  • David Szekeres

    Elected director.

Related articles

$GRIMedAI 9/10

GRI Bio 3Q 2026: EPS ($0.69) — 10-Q Summary

GRI Bio reported no revenue and a narrowed net loss for 3Q 2026, citing reduced spending on GRI-0621 development. The Phase 2a trial met endpoints with no serious adverse events. FDA granted Orphan Drug Designation for GRI-0621. The company plans to file an IND application for GRI-0803 in 2027.

$PMIMed

Biotech Gainers: PMI Revenue Growth, SDOT Earnings Surge, CAPR FDA Update, GRI Data Drive Gains

Picard Medical (PMI) rose 40% after reporting Q2 revenue growth of 39% to $3.0M. Sadot Group (SDOT) surged 100% despite zero revenue, with net income up to $35.2M. Capricor Therapeutics (CAPR) gained 11% after FDA extended review for deramiocel. GRI Bio (GRI) climbed 10% with Phase 2a data selected for ERS 2026. Biomea Fusion (BMEA) rose 14% after completing Phase 2 diabetes trial enrollment. Yarrow Bioscience (YARW) advanced 12% with Graves' disease trial updates.

$GRIMed

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

GRI Bio (NASDAQ: GRI) said the FDA granted Orphan Drug Designation to GRI-0621 (tazarotene) for idiopathic pulmonary fibrosis (IPF). The company noted the designation may provide up to seven years of U.S. market exclusivity after approval, plus potential tax credits and fee waivers. GRI-0621 is an oral RARβ/γ agonist; a Phase 2a trial in 35 patients met endpoints, per the company.

$COSTHigh

The Best Recession-Proof Consumer Stock to Buy With $1,000 Before 2027

Costco (COST) reported Q4 2026 sales growth of 11.2%, with comparable sales up 9.4%. The company announced a $30 special dividend, its highest ever, boosting its stock by 5%. Costco's unique model, offering low prices and membership fees, drives loyalty and sales, especially during economic downturns. Gas stations and e-commerce are key growth drivers, with digitally-enabled sales up 20% YoY.

$MARAMed

MARA prices $185M debt offering after $1.1B Bitcoin sale

MARA priced an $185M debt offering at 8.75% interest, maturing in 2032, to finance its $1.5B acquisition of Long Ridge Energy. The deal includes a 485MW power plant and land for potential data centers. MARA recently sold $1.1B in Bitcoin to repay debt. Long Ridge generated $144M in annualized adjusted EBITDA, but interest payments may consume nearly half.

$RIOLow

Rio Tinto commits US$250m to address damage from Bougainville's Panguna mine

Rio Tinto will contribute $250m to a fund addressing environmental and human rights impacts of the Panguna mine, per an agreement with Bougainville Copper Limited, the Autonomous Bougainville Government, and community leaders. The fund aims to support practical responses to identified impacts and social projects. Details will be developed in consultation with communities.